Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huangqi Yangyuan Formula for Capecitabine-Induced Adverse Reactions in Advanced Colorectal Cancer
NCT07913516Not yet recruiting
- Start
- Jan 2027
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Open-label, single-arm trial. Primary endpoint: Completion Rate of Standardized Capecitabine Chemotherapy at 32 weeks. Planned start Jan 2027; status: not yet recruiting.
Beyond the preview
Go deeper on NCT07913516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07913516.